[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MY132470A - Substituted oxobutyric acids as matrix metalloprotease inhibitors - Google Patents

Substituted oxobutyric acids as matrix metalloprotease inhibitors

Info

Publication number
MY132470A
MY132470A MYPI97002045A MYPI19972045A MY132470A MY 132470 A MY132470 A MY 132470A MY PI97002045 A MYPI97002045 A MY PI97002045A MY PI19972045 A MYPI19972045 A MY PI19972045A MY 132470 A MY132470 A MY 132470A
Authority
MY
Malaysia
Prior art keywords
matrix metalloprotease
substituted
metalloprotease inhibitors
formula
carbons
Prior art date
Application number
MYPI97002045A
Inventor
r brittelli David
Van Zandt Michael
r dixon Brian
Chen Jinshan
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of MY132470A publication Critical patent/MY132470A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

THE PRESENT INVENTION PROVIDES PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CERTAIN CONDITIONS COMPRISING ADMINISTERING AN AMOUNT OF A COMPOUND OR COMPOSITION OF THE INVENTION WHICH IS EFFECTIVE TO INHIBIT THE ACTIVITY OF AT LEAST ONE MATRIX METALLOPROTEASE, RESULTING IN ACHIEVEMENT OF THE DESIRED EFFECT. THE COMPOUNDS OF THE PRESENT INVENTION ARE EITHER OF THE GENERALIZED FORMULA:(FORMULA1)WHEREIN Y IS 0, 2, OR, 3, R, IS 0-6, Z IS (CH2)7 OR (CH2)E-C6H4-(CH2)F, WHEREIN E IS 0-1 AND F IS 1-6, AND R15 IS -H, -CI, -OME OR (FORMULA 2)WHEREIN N IS 0-4, R17 IS C2H5, ALLYL, BENZYL, AND R16 IS (FORMULA 3)WHEREIN T IS 0-1, X IS 0-4, AND R4 IS ONE OF THE FOLLOWING: HALIDE, ALKYL OF 1-6 CARBONS, OR, NR2, NO2 (R = H OR ALKYL OF 1-6 CARBONS
MYPI97002045A 1996-05-15 1997-05-09 Substituted oxobutyric acids as matrix metalloprotease inhibitors MY132470A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64838496A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
MY132470A true MY132470A (en) 2007-10-31

Family

ID=24600568

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI97002045A MY132470A (en) 1996-05-15 1997-05-09 Substituted oxobutyric acids as matrix metalloprotease inhibitors

Country Status (18)

Country Link
EP (1) EP0912487A1 (en)
JP (1) JP3417951B2 (en)
CN (1) CN1163466C (en)
AR (1) AR007096A1 (en)
AU (1) AU727648B2 (en)
CA (1) CA2253869C (en)
CO (1) CO4990925A1 (en)
HR (1) HRP970246B1 (en)
ID (1) ID20291A (en)
MY (1) MY132470A (en)
PA (1) PA8429401A1 (en)
PE (1) PE65998A1 (en)
SV (1) SV1997000034A (en)
TN (1) TNSN97085A1 (en)
TW (1) TW467892B (en)
WO (1) WO1997043238A1 (en)
YU (1) YU18797A (en)
ZA (1) ZA974032B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
WO2009022740A1 (en) * 2007-08-15 2009-02-19 Kyorin Pharmaceutical Co., Ltd. Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as the active ingredient
WO2015150363A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids and use thereof
JP2017511319A (en) 2014-04-03 2017-04-20 バイエル ファーマ アクチエンゲゼルシャフト Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and uses thereof
WO2015150350A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0740655T3 (en) * 1994-01-22 2000-03-27 British Biotech Pharm metalloproteinase

Also Published As

Publication number Publication date
CO4990925A1 (en) 2000-12-26
CA2253869C (en) 2003-04-22
HRP970246A2 (en) 1998-04-30
PE65998A1 (en) 1998-10-20
AU3121997A (en) 1997-12-05
TNSN97085A1 (en) 2005-03-15
YU18797A (en) 1999-11-22
PA8429401A1 (en) 2000-05-24
CA2253869A1 (en) 1997-11-20
TW467892B (en) 2001-12-11
ID20291A (en) 1998-11-19
JPH11509870A (en) 1999-08-31
ZA974032B (en) 1998-02-19
AR007096A1 (en) 1999-10-13
WO1997043238A1 (en) 1997-11-20
SV1997000034A (en) 1999-07-05
HRP970246B1 (en) 2002-04-30
CN1225622A (en) 1999-08-11
EP0912487A1 (en) 1999-05-06
AU727648B2 (en) 2000-12-21
JP3417951B2 (en) 2003-06-16
CN1163466C (en) 2004-08-25

Similar Documents

Publication Publication Date Title
DE69512797D1 (en) Prostaglandin-synthase hemmer
HUT76548A (en) Aryl-sulfonamido-hydroxamic acids of matrix-metalloproteinase-inhibiting activity
BR9713417A (en) Composed of sugar, gelling agent, gelling agent composition, processes for its preparations and gel composition.
CA2264254A1 (en) Phosphinic acid amides as matrix metalloprotease inhibitors
EA200100139A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 2-CHINOLONES
DE3360877D1 (en) Synergistic preservative compositions, products containing them and processes for using them
BR8901097A (en) PROCESS FOR THE PREPARATION OF A BIOCIDAL COMPOSITION
KR940703655A (en) Pharmaceutical Compositions and Methods of Making the Same
EP0331382A3 (en) Transdermal flux enhancing compositions
MY132470A (en) Substituted oxobutyric acids as matrix metalloprotease inhibitors
CA2174544A1 (en) Method for using pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenyl-amino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines as adrenergic agents
NO994659L (en) New pyridine derivatives and pharmaceutical preparations containing them
KR950703941A (en) Nitrogen monoxide synthase inhibitor (NITROGEN MONOXIDE SYNTHESIS INHIBITOR)
ATE239711T1 (en) NEW ALLYTHIOPYRIDAZINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
ATE228303T1 (en) SYNERGISTIC ANTIMICROBIAL COMPOSITIONS CONTAINING 1-HYDROXYMETHYLPYRAZOLE AND PRESERVATIVE AGENTS
KR870010782A (en) Bactericidal Compositions Containing Phosphorous Acid Derivatives
EA200400523A1 (en) DERIVATIVES [[2- (AMINO-3,4-DIOXO-1-CYCLOBUTEN-1-IL) AMINO] ALKYL] ACIDS USED FOR THE TREATMENT OF PAIN
DE59002760D1 (en) K2P PRO STABILIZATION.
DE69515881D1 (en) PESTICIDAL COMPOSITIONS CONTAINING ETHOXYLATED FATTAMINE TO INCREASE THE EFFECTIVENESS OF ENDOTHALL AND ITS SALTS.
SU1687019A3 (en) Method for control of weeds in wheat crops
EA200000681A1 (en) FUNGICIDAL MIXTURE BASED ON AMIDE COMPOUNDS AND Pyridine derivatives
ES8503199A1 (en) Anthelmintics.
IE39679L (en) Methods and compositions for killing parasites of warm¹blooded animals
KR880013896A (en) Benzofuro [3,2-C] quinoline compound
HUT54688A (en) Process for producing compounds utilizable for treating ulcus and pharmaceutical compositions containing them as active components